Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorCedars-Sinai Medical Center
About this trial
All participants will undergo baseline biopsies of subcutaneous abdominal adipose tissue for cellular/molecular profiling via snRNA-seq and metabolic/physiological assessments (insulin sensitivity, glucose tolerance, and β-cell function). Older obese participants will be randomized into three arms: lifestyle intervention (n=24), senolytics (n=24), or placebo (n=24).
Eligibility criteria
Qualifiers
Both Sexes
Age: younger lean group 18-30 years with BMI 18.5-24.9 kg/m2; younger obese group 18-30 with BMI 30.0 -39.9; older obese group ≥ 65 years with BMI 30.0-39.9
All races and ethnic groups
Community dwelling
Disqualifiers
Diabetes, clinically diagnosed or HbA1c > 6.5% and/or fasting plasma glucose > 126 mg/dl and/or use of anti-diabetic medications.
Participating in > 1.5 h of structured exercise/week
Unstable weight (>3% change in last 3 months)
Neurological, musculoskeletal, or other conditions that may limit subject's ability to complete study physical assessment and training
Trial design
Treatments tested in this trial
- Lifestyle Intervention
- Dasatinib 100 MG
- Quercetin 1000mg
- Placebo
- Abdominal adipose tissue biopsy
Treatment groups
160 Participants
are divided into 4 treatment groupsSponsors and collaborators
Cedars-Sinai Medical Center
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov